- Report
- August 2023
- 180 Pages
Global
From €5699EUR$5,950USD£4,853GBP
- Report
- February 2024
- 185 Pages
Global
From €4693EUR$4,900USD£3,997GBP
- Report
- October 2023
- 110 Pages
Global
From €4310EUR$4,500USD£3,670GBP
- Report
- August 2023
- 98 Pages
Europe
From €5699EUR$5,950USD£4,853GBP
- Report
- October 2023
- 130 Pages
Europe
From €4214EUR$4,400USD£3,589GBP
- Report
- November 2023
- 175 Pages
Global
From €4693EUR$4,900USD£3,997GBP
The Recombinant Proteins Manufacturing market is a subset of the biopharmaceuticals industry, which focuses on the production of proteins through recombinant DNA technology. This technology involves the insertion of a gene from one organism into another, allowing for the production of proteins that are not naturally found in the organism. These proteins can be used for a variety of medical applications, such as the treatment of diseases, the development of vaccines, and the production of diagnostic tests. The Recombinant Proteins Manufacturing market is highly competitive, with a number of companies offering a range of products and services. Companies in this market include Lonza, Merck KGaA, Novozymes, and Thermo Fisher Scientific. Show Less Read more